New gene therapy injected into spine aims to fight devastating ALS
Disease control
Not yet recruiting
This is an early-stage trial testing a new gene therapy called SNUG01 for adults with Amyotrophic Lateral Sclerosis (ALS). The main goal is to see if the treatment is safe and tolerable when injected into the spinal fluid. Researchers will also look for early signs that it might …
Phase: PHASE1, PHASE2 • Sponsor: SineuGene Therapeutics Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC